APPOINTMENTS: Valeant, Gilead, Editas, Daiichi, Scancell, PhaseRx, Clintec, Acadia
Executive Summary
This week’s announcements include Valeant’s appointment of an executive vice president finance, Editas Medicine’s appointment of a chief scientific officer, Clintec’s appointment of AstraZeneca’s former global research director and various board appointments by Acadia, Scancell, PhaseRx and Gilead.
You may also be interested in...
Pipeline Watch: Japan Dominates This Week's 26 Approvals Plus 13 Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Executives On The Move: New Hires At Ipsen, Decibel Therapeutics and Reata Pharmaceuticals
Recent executive moves in the industry include new C-suite hires at Editas Medicines, Royalty Pharma and Faron Pharmaceuticals.
Pipeline Watch: Nine Approvals And Nine Phase III Trial Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.